Imugene Limited (ASX:IMU)

Blueprint Medicines Statistics

Total Valuation

Imugene has a market cap or net worth of AUD 79.34 million. The enterprise value is 61.35 million.

Market Cap	79.34M
Enterprise Value	61.35M

Important Dates

The next estimated earnings date is Thursday, August 28, 2025.

Earnings Date	Aug 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Imugene has 288.50 million shares outstanding. The number of shares has increased by 10.54% in one year.

Current Share Class	288.50M
Shares Outstanding	288.50M
Shares Change (YoY)	+10.54%
Shares Change (QoQ)	+1.54%
Owned by Insiders (%)	8.74%
Owned by Institutions (%)	6.93%
Float	254.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	-43.13
PB Ratio	1.25
P/TBV Ratio	2.64
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.47
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.60

Financial Position

The company has a current ratio of 3.08, with a Debt / Equity ratio of 0.25.

Current Ratio	3.08
Quick Ratio	1.96
Debt / Equity	0.25
Debt / EBITDA	n/a
Debt / FCF	-0.15
Interest Coverage	-403.24

Financial Efficiency

Return on equity (ROE) is -100.19% and return on invested capital (ROIC) is -53.79%.

Return on Equity (ROE)	-100.19%
Return on Assets (ROA)	-42.92%
Return on Invested Capital (ROIC)	-53.79%
Return on Capital Employed (ROCE)	-127.75%
Revenue Per Employee	-367,920
Profits Per Employee	-25.86M
Employee Count	5
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -83.82% in the last 52 weeks. The beta is 3.32, so Imugene's price volatility has been higher than the market average.

Beta (5Y)	3.32
52-Week Price Change	-83.82%
50-Day Moving Average	0.41
200-Day Moving Average	0.99
Relative Strength Index (RSI)	34.88
Average Volume (20 Days)	2,992,513

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Imugene had revenue of AUD -1.84 million and -129.30 million in losses. Loss per share was -0.60.

Revenue	-1.84M
Gross Profit	-1.84M
Operating Income	-120.64M
Pretax Income	-129.30M
Net Income	-129.30M
EBITDA	-116.82M
EBIT	-120.64M
Loss Per Share	-0.60

Balance Sheet

The company has 33.74 million in cash and 15.76 million in debt, giving a net cash position of 17.99 million or 0.06 per share.

Cash & Cash Equivalents	33.74M
Total Debt	15.76M
Net Cash	17.99M
Net Cash Per Share	0.06
Equity (Book Value)	63.28M
Book Value Per Share	0.29
Working Capital	55.11M

Cash Flow

In the last 12 months, operating cash flow was -91.93 million and capital expenditures -10.11 million, giving a free cash flow of -102.04 million.

Operating Cash Flow	-91.93M
Capital Expenditures	-10.11M
Free Cash Flow	-102.04M
FCF Per Share	-0.35

Margins

Gross Margin	n/a
Operating Margin	6,557.96%
Pretax Margin	7,028.94%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Imugene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.54%
Shareholder Yield	n/a
Earnings Yield	-162.98%
FCF Yield	-128.62%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 2, 2025. It was a reverse split with a ratio of 0.0294117647.

Last Split Date	Jul 2, 2025
Split Type	Reverse
Split Ratio	0.0294117647

Scores

Imugene has an Altman Z-Score of -1.35 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.35
Piotroski F-Score	1